Marc S Collett
Overview
Explore the profile of Marc S Collett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kankam M, Burns J, Collett M, Corrado M, Hincks J
Antimicrob Agents Chemother
. 2021 Aug;
65(10):e0102921.
PMID: 34370575
V-7404, a direct-acting enterovirus (EV) 3C protease inhibitor, is being developed as a treatment option for serious EV infections, including infections in immunodeficient people excreting vaccine-derived polioviruses. V-7404 may be...
2.
Copelyn J, Hincks J, Wilmshurst J, Petersen W, Howard W, Jallow S, et al.
Pediatr Infect Dis J
. 2020 Mar;
39(5):435-437.
PMID: 32150007
Pocapavir exhibits antiviral activity against both polio and nonpolio enteroviruses. There is limited experience of the use of this investigational drug in young children with enteroviral infection. We describe the...
3.
Brickley E, Connor R, Wieland-Alter W, Collett M, Hartford M, Van Der Avoort H, et al.
BMJ Glob Health
. 2019 Sep;
4(4):e001613.
PMID: 31543993
Background: Our understanding of the acquisition of intestinal mucosal immunity and the control of poliovirus replication and transmission in later life is still emerging. Methods: As part of a 2011...
4.
Collett M, Hincks J, Benschop K, Duizer E, Van Der Avoort H, Rhoden E, et al.
J Infect Dis
. 2016 Dec;
215(3):335-343.
PMID: 27932608
Background: Immunodeficient individuals who excrete vaccine-derived polioviruses threaten polio eradication. Antivirals address this threat. Methods: In a randomized, blinded, placebo-controlled study, adults were challenged with monovalent oral poliovirus type 1...
5.
Tanner E, Liu H, Oberste M, Pallansch M, Collett M, Kirkegaard K
Elife
. 2014 Nov;
3.
PMID: 25365453
The emergence of drug resistance can defeat the successful treatment of pathogens that display high mutation rates, as exemplified by RNA viruses. Here we detail a new paradigm in which...
6.
McKinlay M, Collett M, Hincks J, Oberste M, Pallansch M, Okayasu H, et al.
J Infect Dis
. 2014 Oct;
210 Suppl 1:S447-53.
PMID: 25316866
Chronic prolonged excretion of vaccine-derived polioviruses by immunodeficient persons (iVDPV) presents a personal risk of poliomyelitis to the patient as well as a programmatic risk of delayed global eradication. Poliovirus...
7.
Torres-Torres S, Myers A, Klatte J, Rhoden E, Oberste M, Collett M, et al.
Pediatr Infect Dis J
. 2014 Sep;
34(1):52-4.
PMID: 25229269
Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073)...
8.
Liu H, Roberts J, Moore D, Anderson B, Pallansch M, Pevear D, et al.
Antimicrob Agents Chemother
. 2012 Aug;
56(11):5568-74.
PMID: 22890765
V-073, a small-molecule capsid inhibitor originally developed for nonpolio enterovirus indications is considerably more potent against polioviruses. All poliovirus isolates tested to date (n = 45), including wild, vaccine, vaccine-derived,...
9.
Kouiavskaia D, Dragunsky E, Liu H, Oberste M, Collett M, Chumakov K
Antivir Ther
. 2011 Oct;
16(7):999-1004.
PMID: 22024515
Background: The National Research Council has recommended development of polio antiviral drugs to assist in management of outbreaks and to mitigate adverse consequences of vaccination. V-073 is a small molecule...
10.
Kouiavskaia D, Collett M, Dragunsky E, Sarafanov A, Chumakov K
Clin Vaccine Immunol
. 2011 Jul;
18(8):1387-90.
PMID: 21715577
Immunization of mice with inactivated polio vaccine (IPV) with concurrent dosing of poliovirus antiviral V-073 showed no detrimental impact on the elicitation of serum-neutralizing antibodies. A strategy involving coadministration of...